For example, our analysis suggests that whether ERK activation is responsive to RAF or MEK inhibition by pharmaceutical agents depends on the intra-tumor concentration of pRAF (Fig. 5d) or pMEK (Fig. 5e). Here, MAP2K7 is linked to neoplasm.